Invasiveness and Chemoresistance of Cancer Stem Cells in Colon Cancer
NCT ID: NCT01577511
Last Updated: 2025-11-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
60 participants
OBSERVATIONAL
2012-06-12
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Unfavorable Histological Features on the Oncological Outcomes of Colon Cancer
NCT03794193
Study of Biomarkers in Tissue Samples From Patients With Metastatic Colon Cancer
NCT01012804
A Study of Gemcitabine as an Adjuvant Treatment for Cholangiocarcinoma After Surgical Resection
NCT01043172
Exploratory Study of Intermittent Hypoxia Intervention on Colorectal Cancer
NCT06584318
Multicenter Cohort Prospective Study on Multidisciplinary Treatment of Rectal Cancer
NCT01651026
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Determine the intrinsic properties essential for the dissemination and chemoresistance of these cells capable of initiating tumors
* Identify a "molecular signature" for potential invasiveness and chemoresistance of cells initiating metastases.
* Describe the evolution of patients during 24 months of follow up and correlations with observed cellular profiles.
* Enrich the tumor bank of the institution.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
30 Patients
Patients with operable, stage III or IV, adenocarcino-type colorectal cancer treated at the Nîmes University Hospital.
Intervention: Samples and follow up
Samples and follow up
Samples: Peroperative blood sample plus primary and metastatic tumor biopsies.
Follow-up: disease outcomes assessed at 24 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Samples and follow up
Samples: Peroperative blood sample plus primary and metastatic tumor biopsies.
Follow-up: disease outcomes assessed at 24 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patient must be insured or beneficiary of a health insurance plan
* Patient with adenocarcinoma-type colorectal cancer:
* stage III at diagnosis, surgical resection of the primary tumor proposed.
* stage IV at diagnosis, surgical resection of the primary tumor and possibly of metastases proposed.
* Stage IV who have already undergone surgical excision of the primary tumor, and for whom metastasectomy is now proposed.
Exclusion Criteria
* The patient is in an exclusion period determined by a previous study
* The patient is under judicial protection, under tutorship or curatorship
* The patient refuses to sign the consent
* It is impossible to correctly inform the patient
* Patients for whom surgical resection of the primary tumor is not considered as an option
* PStage IV at diagnosis, but metastasectomy is not considered as an option
* Patients with positive HIV, Hepatitis B or Hepatitis C serology
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Nīmes
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean-François Bourgaux, MD
Role: PRINCIPAL_INVESTIGATOR
Centre Hospitalier Universitaire de Nîmes
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Nîmes - Hôpital Universitaire Carémeau
Nîmes, Gard, France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Grillet F, Bayet E, Villeronce O, Zappia L, Lagerqvist EL, Lunke S, Charafe-Jauffret E, Pham K, Molck C, Rolland N, Bourgaux JF, Prudhomme M, Philippe C, Bravo S, Boyer JC, Canterel-Thouennon L, Taylor GR, Hsu A, Pascussi JM, Hollande F, Pannequin J. Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture. Gut. 2017 Oct;66(10):1802-1810. doi: 10.1136/gutjnl-2016-311447. Epub 2016 Jul 25.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-A01141-40
Identifier Type: OTHER
Identifier Source: secondary_id
LOCAL/2011/JFB-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.